Europe Biosimilars Market by Product Type, End-Use, and Country-wise Insights: Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has recently released a comprehensive report on the Europe Biosimilars Market, providing an in-depth analysis of key market dynamics, including driving factors, emerging trends, opportunities, and challenges. This report offers a detailed examination of the market landscape, enabling stakeholders to make well-informed strategic decisions.

Key Insights:

Europe Biosimilars Market Size (2024E): US$ 12.3 Bn
Projected Market Value (2031F): US$ 33.5 Bn
Market Growth Rate (CAGR 2024 to 2031): 15.4%

Europe Biosimilars Market - Report Scope:

The Europe Biosimilars Market comprises biosimilar drugs that are highly similar to existing biologic reference products in terms of safety, efficacy, and quality. The market is expanding rapidly due to patent expirations of major biologics, increasing prevalence of chronic diseases, and rising healthcare cost pressures. Biosimilars provide cost-effective alternatives to biologics, making essential treatments more accessible to patients and healthcare systems.

Market Growth Drivers:

The Europe Biosimilars Market is driven by the increasing acceptance of biosimilar drugs as a cost-effective alternative to expensive biologics. Growing incidences of chronic diseases, such as cancer and autoimmune disorders, are accelerating demand. Furthermore, supportive regulatory frameworks and government initiatives promoting biosimilar adoption across Europe are contributing to market expansion. Additionally, increased awareness among healthcare providers and patients about the efficacy and safety of biosimilars is boosting market penetration.

Market Restraints:

Despite strong growth potential, the biosimilars market faces challenges, including complex manufacturing processes and stringent regulatory requirements. High costs associated with the development and approval of biosimilars can pose barriers for new entrants. Moreover, reluctance from physicians and patients due to concerns over biosimilar safety and interchangeability with biologics remains a challenge. Competitive pressures from well-established biologic drugs also hinder faster adoption of biosimilars.

Market Opportunities:

The growing focus on reducing healthcare costs and increasing patient access to biologic therapies presents significant opportunities for biosimilar manufacturers. The patent expiry of blockbuster biologics is expected to open lucrative opportunities for biosimilar entry. Strategic collaborations between biosimilar manufacturers and healthcare providers can enhance market access. Expansion of online pharmacies and digital healthcare platforms further broadens the distribution channels, making biosimilars more accessible to patients across Europe.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the Europe Biosimilars Market?
Which biosimilar drugs are experiencing the highest demand across different indications?
How are advancements in biosimilar manufacturing impacting market dynamics?
Who are the key players in the Europe Biosimilars Market, and what strategies are they employing to remain competitive?
What are the emerging trends and future prospects in the Europe Biosimilars Market?

Competitive Intelligence and Business Strategy:

Leading companies in the Europe Biosimilars Market, including Fresenius Kabi, Biogen Inc., and Celltrion, Inc., are focusing on strategic partnerships, innovative biosimilar development, and market expansion to maintain a competitive edge. These players are investing in R&D to ensure biosimilar safety and efficacy while enhancing manufacturing efficiency. Collaborations with healthcare providers and policymakers to boost biosimilar adoption, combined with patient education initiatives, are crucial strategies for market growth. Emphasis on affordability and access to biosimilar treatments ensures a competitive position in the evolving European market.

Key Companies Profiled:

Fresenius Kabi
Biogen Inc.
Celltrion, Inc.
Pfizer Inc.
Amgen Inc.
Samsung Bioepis Co., Ltd.
Biocon
Viatris (Mylan Pharmaceuticals Inc.)
Coherus BioSciences, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Eli Lilly and Company
Bio-Thera Solutions, Ltd.

Europe Biosimilars Industry Segmentation:

By Drug:

Adalimumab
Bevacizumab
Trastuzumab
Rituximab
Infliximab
Etanercept
Epoetin alfa
Filgrastim
Other Biosimilars

By Drug Class:

Antirheumatics
TNF Alfa Inhibitors
VEGF/VEGFR Inhibitors
HER2 Inhibitors
Selective Immunosuppressants
Interleukin Inhibitors

By Indication:

Oncology Diseases
Autoimmune Diseases
Skin Disorders
Inflammatory Bowel Disease (IBD)
Rare Diseases
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

Germany
France
U.K.
Italy
Spain
Russia
Rest of Europe

Product Code: PMRREP34923

1. Executive Summary

1.1. Europe Biosimilars Market Snapshot, 2024 and 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Europe Sectorial Outlook
- 2.3.2. Europe GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Product Adoption Analysis
3.2. Recent Product Approvals and Launches Insights
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.5. PESTLE Analysis
3.6. Porter's Five Force Analysis

4. Europe Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
4.3. Europe Biosimilars Market Outlook: Drug
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug, 2019 - 2023
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug, 2024 - 2031
  - 4.3.3.1. Adalimumab
  - 4.3.3.2. Bevacizumab
  - 4.3.3.3. Trastuzumab
  - 4.3.3.4. Rituximab
  - 4.3.3.5. Infliximab
  - 4.3.3.6. Etanercept
  - 4.3.3.7. Epoetin alfa
  - 4.3.3.8. Filgrastim
  - 4.3.3.9. Other Biosimilars
- 4.3.4. Market Attractiveness Analysis: Drug
4.4. Europe Biosimilars Market Outlook: Drug Class
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019 - 2023
- 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024 - 2031
  - 4.4.3.1. Antirheumatics
  - 4.4.3.2. TNF Alfa Inhibitors
  - 4.4.3.3. VEGF/VEGFR Inhibitors
  - 4.4.3.4. HER2 Inhibitors
  - 4.4.3.5. Selective Immunosuppressant's
  - 4.4.3.6. Interleukin Inhibitors
- 4.4.4. Market Attractiveness Analysis: Drug Class
4.5. Europe Biosimilars Market Outlook: Indication
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019 - 2023
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
  - 4.5.3.1. Oncology Diseases
  - 4.5.3.2. Autoimmune Diseases
  - 4.5.3.3. Skin Disorders
  - 4.5.3.4. Inflammatory Bowel Disease (IBD)
  - 4.5.3.5. Rare Diseases
  - 4.5.3.6. Others
- 4.5.4. Market Attractiveness Analysis: Indication
4.6. Europe Biosimilars Market Outlook: Distribution Channel
- 4.6.1. Introduction / Key Findings
- 4.6.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019 - 2023
- 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
  - 4.6.3.1. Hospital Pharmacies
  - 4.6.3.2. Retail Pharmacies
  - 4.6.3.3. Online Pharmacies
- 4.6.4. Market Attractiveness Analysis: Distribution Channel

5. Europe Biosimilars Market Outlook: Country

5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Country, 2019 - 2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024 - 2031
- 5.3.1. Germany
- 5.3.2. France
- 5.3.3. U.K.
- 5.3.4. Italy
- 5.3.5. Spain
- 5.3.6. Russia
- 5.3.7. Rest of Europe
5.4. Market Attractiveness Analysis: Country

6. Germany Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 6.2.1. By Drug
- 6.2.2. By Drug Class
- 6.2.3. By Indication
- 6.2.4. By Distribution Channel
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug, 2024 - 2031
- 6.3.1. Adalimumab
- 6.3.2. Bevacizumab
- 6.3.3. Trastuzumab
- 6.3.4. Rituximab
- 6.3.5. Infliximab
- 6.3.6. Etanercept
- 6.3.7. Epoetin alfa
- 6.3.8. Filgrastim
- 6.3.9. Other Biosimilars
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024 - 2031
- 6.4.1. Antirheumatics
- 6.4.2. TNF Alfa Inhibitors
- 6.4.3. VEGF/VEGFR Inhibitors
- 6.4.4. HER2 Inhibitors
- 6.4.5. Selective Immunosuppressant's
- 6.4.6. Interleukin Inhibitors
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 6.5.1. Oncology Diseases
- 6.5.2. Autoimmune Diseases
- 6.5.3. Skin Disorders
- 6.5.4. Inflammatory Bowel Disease (IBD)
- 6.5.5. Rare Diseases
- 6.5.6. Others
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
- 6.6.1. Hospital Pharmacies
- 6.6.2. Retail Pharmacies
- 6.6.3. Online Pharmacies
6.7. Market Attractiveness Analysis

7. France Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 7.2.1. By Drug
- 7.2.2. By Drug Class
- 7.2.3. By Indication
- 7.2.4. By Distribution Channel
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug, 2024 - 2031
- 7.3.1. Adalimumab
- 7.3.2. Bevacizumab
- 7.3.3. Trastuzumab
- 7.3.4. Rituximab
- 7.3.5. Infliximab
- 7.3.6. Etanercept
- 7.3.7. Epoetin alfa
- 7.3.8. Filgrastim
- 7.3.9. Other Biosimilars
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024 - 2031
- 7.4.1. Antirheumatics
- 7.4.2. TNF Alfa Inhibitors
- 7.4.3. VEGF/VEGFR Inhibitors
- 7.4.4. HER2 Inhibitors
- 7.4.5. Selective Immunosuppressant's
- 7.4.6. Interleukin Inhibitors
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 7.5.1. Oncology Diseases
- 7.5.2. Autoimmune Diseases
- 7.5.3. Skin Disorders
- 7.5.4. Inflammatory Bowel Disease (IBD)
- 7.5.5. Rare Diseases
- 7.5.6. Others
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
- 7.6.1. Hospital Pharmacies
- 7.6.2. Retail Pharmacies
- 7.6.3. Online Pharmacies
7.7. Market Attractiveness Analysis

8. UK Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 8.2.1. By Drug
- 8.2.2. By Drug Class
- 8.2.3. By Indication
- 8.2.4. By Distribution Channel
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug, 2024 - 2031
- 8.3.1. Adalimumab
- 8.3.2. Bevacizumab
- 8.3.3. Trastuzumab
- 8.3.4. Rituximab
- 8.3.5. Infliximab
- 8.3.6. Etanercept
- 8.3.7. Epoetin alfa
- 8.3.8. Filgrastim
- 8.3.9. Other Biosimilars
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024 - 2031
- 8.4.1. Antirheumatics
- 8.4.2. TNF Alfa Inhibitors
- 8.4.3. VEGF/VEGFR Inhibitors
- 8.4.4. HER2 Inhibitors
- 8.4.5. Selective Immunosuppressant's
- 8.4.6. Interleukin Inhibitors
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 8.5.1. Oncology Diseases
- 8.5.2. Autoimmune Diseases
- 8.5.3. Skin Disorders
- 8.5.4. Inflammatory Bowel Disease (IBD)
- 8.5.5. Rare Diseases
- 8.5.6. Others
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
- 8.6.1. Hospital Pharmacies
- 8.6.2. Retail Pharmacies
- 8.6.3. Online Pharmacies
8.7. Market Attractiveness Analysis

9. Italy Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 9.2.1. By Drug
- 9.2.2. By Drug Class
- 9.2.3. By Indication
- 9.2.4. By Distribution Channel
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug, 2024 - 2031
- 9.3.1. Adalimumab
- 9.3.2. Bevacizumab
- 9.3.3. Trastuzumab
- 9.3.4. Rituximab
- 9.3.5. Infliximab
- 9.3.6. Etanercept
- 9.3.7. Epoetin alfa
- 9.3.8. Filgrastim
- 9.3.9. Other Biosimilars
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024 - 2031
- 9.4.1. Antirheumatics
- 9.4.2. TNF Alfa Inhibitors
- 9.4.3. VEGF/VEGFR Inhibitors
- 9.4.4. HER2 Inhibitors
- 9.4.5. Selective Immunosuppressant's
- 9.4.6. Interleukin Inhibitors
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 9.5.1. Oncology Diseases
- 9.5.2. Autoimmune Diseases
- 9.5.3. Skin Disorders
- 9.5.4. Inflammatory Bowel Disease (IBD)
- 9.5.5. Rare Diseases
- 9.5.6. Others
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
- 9.6.1. Hospital Pharmacies
- 9.6.2. Retail Pharmacies
- 9.6.3. Online Pharmacies
9.7. Market Attractiveness Analysis

10. Spain Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 10.2.1. By Drug
- 10.2.2. By Drug Class
- 10.2.3. By Indication
- 10.2.4. By Distribution Channel
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug, 2024 - 2031
- 10.3.1. Adalimumab
- 10.3.2. Bevacizumab
- 10.3.3. Trastuzumab
- 10.3.4. Rituximab
- 10.3.5. Infliximab
- 10.3.6. Etanercept
- 10.3.7. Epoetin alfa
- 10.3.8. Filgrastim
- 10.3.9. Other Biosimilars
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024 - 2031
- 10.4.1. Antirheumatics
- 10.4.2. TNF Alfa Inhibitors
- 10.4.3. VEGF/VEGFR Inhibitors
- 10.4.4. HER2 Inhibitors
- 10.4.5. Selective Immunosuppressant's
- 10.4.6. Interleukin Inhibitors
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 10.5.1. Oncology Diseases
- 10.5.2. Autoimmune Diseases
- 10.5.3. Skin Disorders
- 10.5.4. Inflammatory Bowel Disease (IBD)
- 10.5.5. Rare Diseases
- 10.5.6. Others
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
- 10.6.1. Hospital Pharmacies
- 10.6.2. Retail Pharmacies
- 10.6.3. Online Pharmacies
10.7. Market Attractiveness Analysis

11. Russia Biosimilars Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
- 11.2.1. By Drug
- 11.2.2. By Drug Class
- 11.2.3. By Indication
- 11.2.4. By Distribution Channel
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug, 2024 - 2031
- 11.3.1. Adalimumab
- 11.3.2. Bevacizumab
- 11.3.3. Trastuzumab
- 11.3.4. Rituximab
- 11.3.5. Infliximab
- 11.3.6. Etanercept
- 11.3.7. Epoetin alfa
- 11.3.8. Filgrastim
- 11.3.9. Other Biosimilars
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024 - 2031
- 11.4.1. Antirheumatics
- 11.4.2. TNF Alfa Inhibitors
- 11.4.3. VEGF/VEGFR Inhibitors
- 11.4.4. HER2 Inhibitors
- 11.4.5. Selective Immunosuppressant's
- 11.4.6. Interleukin Inhibitors
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024 - 2031
- 11.5.1. Oncology Diseases
- 11.5.2. Autoimmune Diseases
- 11.5.3. Skin Disorders
- 11.5.4. Inflammatory Bowel Disease (IBD)
- 11.5.5. Rare Diseases
- 11.5.6. Others
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024 - 2031
- 11.6.1. Hospital Pharmacies
- 11.6.2. Retail Pharmacies
- 11.6.3. Online Pharmacies
11.7. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Share Analysis, 2023
12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Siemens Healthineers
  - 12.3.1.1. Overview
  - 12.3.1.2. Segments and Product
  - 12.3.1.3. Key Financials
  - 12.3.1.4. Market Developments
  - 12.3.1.5. Market Strategy
- 12.3.2. Biogen Inc.
- 12.3.3. Celltrion, Inc.
- 12.3.4. Pfizer Inc.
- 12.3.5. Amgen Inc.
- 12.3.6. Samsung Bioepis Co., Ltd.
- 12.3.7. Biocon
- 12.3.8. Viatris (Mylan Pharmaceuticals Inc.)
- 12.3.9. Coherus BioSciences, Inc.
- 12.3.10. Boehringer Ingelheim Pharmaceuticals, Inc.
- 12.3.11. Eli Lilly and Company
- 12.3.12. Bio-Thera Solutions, Ltd.

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations